



1740
AF 8

PATENT
Customer No. 22,852
Attorney Docket No. 03495.0217-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Schwartz et al.) Group Art Unit: 1648
Application No.: 10/083,678) Examiner: PARKIN, J.
Filed: February 27, 2002) Confirmation No. 9442
For: MHC-I-RESTRICTED PRESENTATION OF HIV-1 VIRION ANTIGENS
WITHOUT VIRAL REPLICATION. APPLICATION TO THE STIMULATION OF
CTL AND VACCINATION *IN VIVO*; ANALYSIS OF VACCINATING
COMPOSITION *IN VITRO*

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Applicants enclose the following papers:

1. Information Disclosure Statement under 37 C.F.R. § 1.97(d) (2 pages);
2. PTO Form SB/08 (1 page) and one document; and
3. \$180 Check for requisite Information Disclosure Fees.

Kindly associate this submission with the above-identified application.


Please grant any extensions of time required to enter these papers and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: May 19, 2005

By: _____

A handwritten signature in black ink, appearing to read 'S. Arrigo', written over a horizontal line.

Salvatore J. Arrigo
Reg. No. 46,063
Tel.: (202) 408-4160
Fax.: (202) 408-4400
E-mail: arrigos@finnegan.com



PATENT
Customer No. 22,852
Attorney Docket No. 03495.0217-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Schwartz et al.) Group Art Unit: 1648
)
Application No.: 10/083,678) Examiner: PARKIN, J.
)
Filed: February 27, 2002) Confirmation No. 9442
)
For: MHC-I-RESTRICTED PRESENTATION OF HIV-1 VIRION ANTIGENS
WITHOUT VIRAL REPLICATION. APPLICATION TO THE STIMULATION OF
CTL AND VACCINATION *IN VIVO*; ANALYSIS OF VACCINATING
COMPOSITION *IN VITRO*

Mail Stop AF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(d)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), applicants bring to the attention of the Examiner the document on the attached listing. This Information Disclosure Statement is being filed after a Final Action but before payment of the Issue Fee and is accompanied by a fee of \$180.00 as specified under § 1.17(p) and a certification as specified under § 1.97(e). Applicants respectfully request that the Examiner consider the listed document and indicate that it was considered by making appropriate notations on the attached form.

The document listed in this Information Disclosure Statement was first cited in a communication from the European Patent Office in a counterpart foreign application, and this Information Disclosure Statement is being filed within three months of the mailing date of that communication.

A copy of the listed foreign and non-patent literature document is attached.

Copies of U.S. patent publications are not enclosed.

Applicants respectfully request that the Examiner consider the listed document and indicate that it was considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed document is material or constitute "prior art." If the Examiner applies the document as prior art against any claims in the application and applicants determine that the cited document does not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should it be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: May 19, 2005

By: 

Salvatore J. Arrigo, Reg. No. 46,063
Tel.: (202) 408-4160 Fax.: (202) 408-4400
E-mail: arrigos@finnegan.com



| | | | | | |
|---|---|----|---|--------------------------|-------------------|
| PDS Form PTO/SB/08: Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/083,678 |
| | | | | Filing Date | February 27, 2002 |
| | | | | First Named Inventor | SCHWARTZ et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | J. PARKIN |
| Sheet | 1 | of | 1 | Attorney Docket Number | 03495.0217-00 |

| U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS | | | | | |
|---|--------------------------|--|--|--|---|
| Examiner Initials | Cite No. ¹ | Document Number | Issue or Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--------------------------------|--|--|--------------------------|
| Examiner Initials | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | Translation ⁶ |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|--|--------------------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation ⁶ |
| | | HAGLUND et al., "Expression of Human Immunodeficiency Virus Type 1 Gag Protein Precursor and Envelope Proteins from a Vesicular Stomatitis Virus Recombinant: High-Level Production of Virus-like Particles Containing HIV Envelope," Virology Vol. 268:112-121 (2000) | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.